MXMin Xu

Min Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Min Xu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Keqiang He

    Department of Anesthesiology, First Affiliated Hospital of University of Science and Technology of China, Hefei, People's Republic of China

    4 shared publications
  • Sheng Wang

    Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China

    4 shared publications
  • Chen Gao

    Department of Anesthesiology, First Affiliated Hospital of University of Science and Technology of China, Hefei, People’s Republic of China

    3 shared publications
  • Yan Meng

    Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China

    3 shared publications
  • Jiawei Xiao

    2 shared publications
  • Sheng Ding

    Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Effect of Liposomal Bupivacaine for Fascia Iliaca Compartment Block on Early Postoperative Recovery Quality in Elderly Patients Undergoing Total Hip Arthroplasty: A Retrospective Cohort Study

    by Zaibao Wang, Chunliu Li, Qing Shao, Xiangru Liu, Jiawei Xiao, Min Xu, Sheng Wang, Keqiang He

    This retrospective cohort study aimed to determine whether liposomal bupivacaine used in suprainguinal fascia iliaca compartment block (S-FICB) is superior to 0.33% ropivacaine in improving the quality of early postoperative recovery in elderly patients with hip fractures who underwent total hip arthroplasty (THA). Outcomes included: 15-item Quality of Recovery Scale (QoR-15); Numerical Rating Scale (NRS) for pain; Pittsburgh Sleep Quality Index (PSQI); Harris Hip Score; plus rescue analgesic use and hospital stay. It should be noted that the observed benefits are limited to the early postoperative period. A retrospective analysis was conducted on 200 elderly patients (aged 65–85 years) with hip fractures who underwent total hip arthroplasty (THA). Patients were divided into two groups based on the local anesthetic they received for S-FICB: the ropivacaine group (RG group, n = 100) or the liposomal bupivacaine group (LBG group, n = 100). QoR-15 and Harris scores were recorded preoperatively and on days 1, 3, 5 postoperatively. NRS and PSQI were recorded preoperatively and on days 1, 2, 3, 5. Rescue analgesic consumption and hospital stay were recorded. On postoperative day 1, QoR-15 was higher in LBG vs RG (113.25±3.825 vs 105.6±3.75, P=0.0004). NRS was lower in LBG within the first 48 postoperative hours (P < 0.05). PSQI was better in LBG on postoperative days 1 and 2 (P < 0.01). Harris score was higher in LBG on postoperative day 1 (P = 0.0007). Rescue analgesic use and postoperative hospital stay were lower in LBG (P < 0.05). Liposomal bupivacaine is superior to ropivacaine in the early postoperative recovery and analgesia of elderly THA patients. However, this advantage is primarily limited to the early postoperative period. Prospective validation is required given the retrospective design.


  • Open Access

    Determining the Median Effective Dose of Remimazolam for Anesthesia Induction in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: An Age-Stratified Study

    by Yan Meng, Youping Song, Chen Gao, Sheng Wang, Keqiang He, Min Xu

    Background: Endoscopic Retrograde Cholangiopancreatography (ERCP) requires precise anesthesia control. Remimazolam is ideal for induction due to its rapid onset and minimal cardiorespiratory impact, but its optimal dose across ages is unclear. This study determined the median effective dose (ED50) of remimazolam for ERCP induction and assessed the influence of age. Methods: In this prospective study, 110 patients aged 50– 89 years (ASA I–III, BMI 18– 30 kg/m2) scheduled for ERCP were stratified into four age groups: R1 (50– 59), R2 (60– 69), R3 (70– 79), and R4 (80– 89). The Dixon up-and-down method was used, with the initial dose for R1 set at 0.1 mg/kg remimazolam and sequentially reduced by 0.01 mg/kg for the first patient in each older group. Patients received 0.1 μg/kg sufentanil prior to the intravenous administration of a predetermined dose of remimazolam. Anesthesia success was defined as a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score of 0 at 3 minutes after intravenous remimazolam administration, which served as the endpoint for determining the effective induction dose. Results: To determine the effective dose for inducing anesthesia, the ED50 of remimazolam were calculated for groups R1 to R4 as follows: 0.122, 0.108, 0.093, and 0.078 mg/kg, respectively. Similarly, the dosage required to achieve ED95 for the same groups was determined to be 0.132, 0.122, 0.113, and 0.090 mg/kg.Bivariate and multivariable linear regression analyses confirmed a significant inverse correlation between age and remimazolam dose requirement (r = − 0.829, p < 0.001), with age remaining an independent predictor after adjusting for confounders. Conclusion: This study confirms a significant and independent inverse correlation between age and the required induction dose of remimazolam for ERCP. The ED50 decreases progressively with advancing age. We recommend a tailored reduction in the remimazolam induction dose for geriatric patients to enhance safety.


  • Open Access

    Effect of Fospropofol Disodium on Perioperative Neurocognitive Function in Elderly Patients Undergoing Total Hip Arthroplasty

    by Hongrui Zhu, Zaibao Wang, Sheng Ding, Chunliu Li, Li Xie, Yan Meng, Jiawei Xiao, Wuyang Zhang, Min Xu, Chen Gao, et al.

    Objective: This study aimed to compare the effects of fospropofol disodium and propofol on perioperative neurocognitive function in elderly patients undergoing total hip arthroplasty (THA), evaluating the non-inferiority of fospropofol disodium in preventing or reducing perioperative neurocognitive disorders (PND) and exploring optimal clinical anesthesia strategies. Methods: A total of 180 elderly patients (aged 65~80 years) scheduled for THA between November 2022 and November 2024 were randomly assigned to the fospropofol disodium group (Group F, n=90) or the propofol group (Group P, n=90). Cognitive function was assessed preoperatively (1 day before surgery) and postoperatively (1, 3, 7 days, and 1 month) using the Modified Mini-Mental State Examination (MMSE), 3-Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM), Digit Span Test (DST), Verbal Fluency Test (VFT), and Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). The incidence of postoperative cognitive dysfunction (POCD) and delirium (POD), hemodynamic parameters, and adverse events were compared between the two groups. Results: No significant differences were observed between the two groups in the incidence of POCD (p> 0.05) or POD (p> 0.05) at any postoperative time point. At the time point of 10 minutes after bone cement implantation (T4), the heart rate of patients in the Group F was higher than that of Group P (p < 0.0001). At the time of discharge from the PACU, the heart rate of patients in the Group F was lower than that of the Group P (p = 0.037). Group F exhibited higher mean arterial pressure (MAP) at the beginning of the operation (p=0.022) and a longer extubation time and waking time (p < 0.001) but had significantly lower incidences of injection pain (p=0.018) and postoperative nausea and vomiting (p=0.037). Binary logistic regression identified age as an independent risk factor for PND [OR=1.149, p=0.006], while preoperative MMSE score was a protective factor [OR=0.693, p = 0.002]. Conclusion: Fospropofol disodium may be a viable alternative in settings where injection pain and PONV are primary concerns, provided that hemodynamic stability is actively managed in elderly THA patients, with non-inferior efficacy in preventing PND compared to propofol and fewer adverse effects. Age and preoperative cognitive function are critical predictors of PND, warranting careful consideration in perioperative management.


  • Open Access

    The Analgesic Efficacy of Liposomal Bupivacaine in Adductor Canal Block Following Knee Arthroplasty: A Single-Center, Prospective, Randomized and Controlled Clinical Trial

    by Min Xu, Sheng Wang, Yan Meng, Chen Gao, Lin Liu, Ji Yuan, Sheng Ding, Xiaoqing Chai, Keqiang He

    Purpose: This study aimed to compare the analgesic efficacy of liposomal bupivacaine with that of traditional ropivacaine in adductor canal blocks for patients undergoing knee arthroplasty. Patients and Methods: A total of 119 consenting participants, who were scheduled for elective knee arthroplasty (including total knee replacement and unicompartmental knee replacement) under general anesthesia, were randomly assigned to either receive an ultrasound-guided adductor canal block with ropivacaine or liposomal bupivacaine. The primary endpoint of this study was the pain scores at 2, 24, 48, and 72 hours post-surgery. Secondary outcomes included nausea, vomiting, and pruritis, the ability to engage in physiotherapy on the first day after surgery, postoperative exercise, patient satisfaction with anesthesia, postoperative recovery index, and patient-controlled analgesic presses (12– 48 hours) for both groups. Results: The Visual Analog Scale (VAS), assessed from 24 to 72 hours post-follow-up, demonstrated that patients receiving ropivacaine had higher median VAS scores compared to those in the liposomal bupivacaine group, both at rest and during exercise. The weighted AUC numerical rating scale pain scores whether at rest or move in the liposomal bupivacaine group was lower than the standard bupivacaine group with statistical significance. Whether it is 0– 24 hours (Rest 58.00 [53.75, 69.00] vs 48.00 [46.50, 58.00]; Move:57.00 [46.00, 59.00] vs 36.00 [35.00, 48.00]) or 0– 72 hours (Rest 214.00 [197.75, 237.00] vs 165.00 [143.50, 180.00]; Move:202.00 [190.00, 215.75]vs.156.00 [131.00, 178.00]) From 12 to 48 hours, the ropivacaine group had a significantly higher number of PCIA presses. The liposomal bupivacaine group also achieved greater pain-free bending angles and walking distances compared to the ropivacaine group. Conclusion: Liposomal bupivacaine used in adductor canal block provides extended pain relief in knee arthroplasty patients, aiding early rehabilitation.